Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK

Executive Summary

GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.

You may also be interested in...



EU Confirms Sirukumab Filing Withdrawal, J&J Moves On

Janssen-Cilag has withdrawn the EU marketing application for the IL-6 inhibitor sirukumab, with the CHMP saying the long-term safety of sirukumab had not been well characterized and further clinical studies were required, a conclusion also drawn earlier by the US FDA.

J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.

Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles

FDA advisory committee's concerns about a mortality imbalance in Plivensia clinical trials would appear to reduce the odds that the interleukin-6 inhibitor will reach the US market in the near term.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099210

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel